The following is a summary of “A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217),” published in the April 2025 issue of BMC Cancer by Capdevila et al. Neuroendocrine tumors (NETs) of […]
The post Evaluating Radioligand Therapy Versus Everolimus in Lung NETs first appeared on Physician’s Weekly.
